• OPEN AN ACCOUNT
Indian Indices
Nifty
25,541.80 24.75
(0.10%)
Sensex
83,697.29 90.83
( 0.11%)
Bank Nifty
57,459.45 146.70
( 0.26%)
Nifty IT
38,833.15 -116.85
( -0.30%)
Global Indices
Nasdaq
44,512.09 396.31
(0.90%)
Dow Jones
6,218.43 -7.52
(-0.12%)
Hang Seng
39,928.49 -558.90
(-1.38%)
Nikkei 225
8,785.33 24.37
(0.28%)
Forex
USD-INR
85.41 -0.32
(-0.37%)
EUR-INR
100.07 -0.25
(-0.25%)
GBP-INR
117.16 -0.49
(-0.42%)
JPY-INR
0.59 0.00
(-0.52%)

EQUITY - MARKET SCREENER

Ushdev International Ltd
Industry :  Power Generation And Supply
BSE Code
ISIN Demat
Book Value()
511736
INE981D01025
-94.7609293
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
USHDEVINT
0
34.86
EPS(TTM)
Face Value()
Div & Yield %
0
1
0
 

sun pharmaceuticals industries ltd
Sun Pharma inks global licensing agreement with Philogen
Oct 01,2024

Sun Pharmaceutical Industries and Philogen S.p.A (Philogen) today announced that they have entered into a global licensing agreement for commercializing Philogen's specialty product, Fibromun (L19TNF).

Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.

Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.

Philogen will complete the ongoing pivotal clinical trials for the product, pursue Marketing Authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio. Other financial terms were not disclosed.